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Stanford University School of Medicine, Stanford, CA, United StatesThe meta-analysis of prevalence of anxiety disorders among pa- respectively. Moreover, the utility of other medications, such as
tients with bipolar disorder in this issue of E-Biomedicine (Nabavi
et al., 2015) provides a timely summary of knowledge to date regard-
ing this important co-occurrence of psychiatric conditions. The au-
thors report that 43% of people with bipolar disorder have had at
least one lifetime anxiety disorder. This ﬁgure is very similar to the
45% rate of people with bipolar disorder having had at least one life-
time anxiety disorder recently reported in a recent different meta-
analysis, based on an only partially (less than half) overlapping set
of studies (Pavlova et al., 2015).
Individuals with bipolar disorder commonly have had more than
one lifetime anxiety disorder. Indeed, the sum of the lifetime preva-
lences reported by Nabavi and associates for the individual anxiety dis-
orders (panic disorder, generalized anxiety disorder, social anxiety
disorder, post-traumatic stress disorder, speciﬁc phobia, obsessive com-
pulsive disorder, and agoraphobia) was approximately twice as high
(nearly 85%) as that for any anxiety disorder. Nabavi and associates'
43% meta-analytic lifetime prevalence rate of any anxiety disorder is
slightly below the 48% mid-point between the lowest (17%) (Angst
et al., 2013) and highest (79%) (Pini et al., 1997) lifetime prevalence
rates reported in the individual studies reviewed, highlighting the sub-
stantial heterogeneity of anxiety disorder lifetime prevalence across
samples. This important heterogeneitywas evident despite only includ-
ing studies that used the rigorous approach of using interview-based di-
agnosis for comorbid anxiety disorders. As such heterogeneity likely has
meaningful relationships with not only neurobiology but also clinical
outcomes, researchers and clinicians alike need to account for anxiety
disorder comorbidity in their efforts to understand, diagnose, and
treat patients with complicated bipolar disorders.
The very substantial percentage of bipolar disorder patients with a
lifetime anxiety disorder has particularly profound clinical implications.
Anxiety disorders and alcohol/substance use disorders commonly co-
occur with one another and with mood disorders. Indeed, anxiety
disorders and alcohol/substance use disorders constitute the two most
commonly encountered comorbid conditions in people with bipolar
disorder (Merikangas et al., 2007). As the authors point out, manage-
ment of comorbid anxiety disorders in bipolar disorder patients with
antidepressants and benzodiazepines may be limited by the risks of
mood destabilization and exacerbation of substance use problems,DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.006.
http://dx.doi.org/10.1016/j.ebiom.2015.09.022
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article undersecond-generation antipsychotics may be limited by inefﬁcacy and/or
adverse effects, whereas the utility of adjunctive psychotherapy may
be limited by inefﬁcacy, particularly in individuals challenged by more
than one anxiety disorder in addition to bipolar disorder (Deckersbach
et al., 2014).
Like many good studies, Nabavi and associates' article raises more
questions than it answers. Prior studies have consistently reported
associations in bipolar disorder patients between comorbid anxiety
disorders and multiple unfavorable illness characteristics, including
earlier bipolar disorder onset age, and increased suicidality, rate of
substance use disorders, and mood episode severity and frequency,
as well as treatment resistance. Teasing out how this multivariate
“web of causality” of factors (that include comorbid anxiety disor-
ders) mediates poorer outcomes could help inform prioritization of
efforts to enhance prognosis in patients with bipolar disorder and
comorbid anxiety disorders. In addition, Nabavi and associates'
study (which focused on individuals with bipolar I disorder) did
not address the important question of putative differential lifetime
anxiety disorder comorbidity rates in people with bipolar I disorder
compared to those with bipolar II disorder. Finally, Nabavi and asso-
ciates' study did not address important questions regarding the de-
gree to which co-occurring anxiety and bipolar disorders may be
independent or inter-related problems.
Although meta-analysis of the clinical correlates of anxiety disorder
comorbidity in bipolar disorder patients was beyond the scope of this
paper, and as pointed out by the authors, may have substantial feasibil-
ity limitations; such information could importantly inform clinical ef-
forts to mitigate the adverse effects of concurrent anxiety disorders in
patients with bipolar disorder. Information regarding the impact of in-
terventions focusing on relieving comorbid anxiety upon overall mood
and anxiety disorder illness burden in individuals remains an important
research priority.
Nevertheless, Nabavi and associates' study leaves both researchers
and clinicianswith a very clear take-homemessage – that the very com-
mon occurrence of anxiety disorders in people with bipolar disorder
contributes in an important fashion to challenges faced by those striving
to accurately assess neurobiology and diagnosis and to provide effective
treatment for individuals struggling with both conditions.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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